% (95 % CI) | ||||
---|---|---|---|---|
Adverse reaction type | 2011 | Previous years | P-value | |
ARV | Related reactions (all) | 80.9 % (77.4 %–84.4 %) | 81.3 % (78.1 %–84.5 %) | 0.87 |
NVP-related | Skin and liver | 43.2 % (38.7 %–47.7 %) | 16.7 % (13.7 %–19.7 %) | <0.0001 |
Skin (all) | 31.2 % (27.0 %–35.5 %) | 11.8 % (9.2 %–14.4 %) | <0.0001 | |
Skin: severe | 22.7 % (18.9 %–26.5 %) | 5.6 % (3.7 %%–7.5 %) | <0.0001 | |
Skin: mild/moderate | 8.5 % (6.0 %–11.0 %) | 6.2 % (4.2 %–8.2 %) | 0.16 | |
Liver (all) | 12.1 % (9.2 %–15.0 %) | 4.9 % (3.1 %–6.7 %) | <0.0001 | |
Liver: severe | 8.5 % (6.0 %–11.0 %) | 2.2 % (1.0 %–3.4 %) | <0.0001 | |
Liver: mild/moderate | 2.7 % (1.0 %–4.4 %) | 2.4 % (1.2 %–3.6 %) | 0.73 | |
Other medicines | Skin and liver | 5.0 % (3.0 %–7.0 %) | 9.9 % (7.5 %–12.3 %) | 0.002 |
NVP-related reactions for | Females | 29.5 % (25.4 %–33.6 %) | 12.5 % (9.8 %–15.2 %) | <0.0001 |
Females: severe | 21.6 % (17.9 %–25.3 %) | 5.6 % (3.7 %–7.5 %) | <0.0001 | |
Females: skin-severe | 17.3 % (13.9 %–20.7 %) | 4.0 % (2.4 %–5.6 %) | <0.0001 | |
Females: liver-severe | 4.3 % (2.5 %–6.1 %) | 1.5 % (0.5 %–2.5 %) | 0.0072 | |
Males | 13.7 % (10.6 %–16.8 %) | 3.9 % (2.3 %–5.5 %) | <0.0001 | |
Males: severe | 9.6 % (6.9 %–12.3 %) | 2.2 % (1.0 %–3.4 %) | <0.0001 | |
Males: skin-severe | 5.4 % (3.4 %–7.4 %) | 1.5 % (0.5 %–2.5 %) | 0.0007 | |
Males: liver-severe | 4.2 % (2.4 %–6.0 %) | 0.7 % (0.0 %–1.4 %) | 0.0003 |